Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.

Hirt, Christian K; Booij, Tijmen H; Grob, Linda; Simmler, Patrik; Toussaint, Nora C; Keller, David; Taube, Doreen; Ludwig, Vanessa; Goryachkin, Alexander; Pauli, Chantal; Lenggenhager, Daniela; Stekhoven, Daniel J; Stirnimann, Christian U; Endhardt, Katharina; Ringnalda, Femke; Villiger, Lukas; Siebenhüner, Alexander; Karkampouna, Sofia; De Menna, Marta; Beshay, Janette; ... (2022). Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. Cell genomics, 2(2), p. 100095. Elsevier 10.1016/j.xgen.2022.100095

Preview

Text 1-s2.0-S2666979X2200012X-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (5MB) | Preview

Pancreatic cancer (PDAC) is a highly aggressive malignancy for which the identification of novel therapies is urgently needed. Here, we establish a human PDAC organoid biobank from 31 genetically distinct lines, covering a representative range of tumor subtypes, and demonstrate that these reflect the molecular and phenotypic heterogeneity of primary PDAC tissue. We use CRISPR-Cas9 genome editing and drug screening to characterize drug-gene interactions with ARID1A and BRCA2. We find that missense- but not frameshift mutations in the PDAC driver gene ARID1A are associated with increased sensitivity to the kinase inhibitors dasatinib (p < 0.0001) and VE-821 (p < 0.0001). We conduct an automated drug-repurposing screen with 1,172 FDA-approved compounds, identifying 26 compounds that effectively kill PDAC organoids, including 19 chemotherapy drugs currently approved for other cancer types. We validate the activity of these compounds in vitro and in vivo. The in vivo validated hits include emetine and ouabain, compounds which are approved for non-cancer indications and which perturb the ability of PDAC organoids to respond to hypoxia. Our study provides proof-of-concept for advancing precision oncology and identifying candidates for drug repurposing via genome editing and drug screening in tumor organoid biobanks.

Interest & Impact

Downloads

49 since deposited on 22 Feb 2022
39 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item